A Phase 1/2 interventional study of Placebo and Dapagliflozin (10mg Tab) in Rheumatoid Arthritis (RA, sponsored by Tanta University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Tanta University · Phase 1/2, Interventional, and Treatment
Among 15 studies in Arthritis, Rheumatoid by Tanta University — 11 open to participants now, 11 under way, 3 of them phase 3. Arthritis, Rheumatoid · Tanta University.
Among the 15 studies in Arthritis, Rheumatoid by Tanta University, this one has the largest planned enrollment of the 14 interventional ones that give a count, is one of 5 that started in 2026, is the only one in phase 1/2, reaches primary completion later than 9 of the 10 other live ones, and was the 15th registered.
3,334 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →11 of the 15 studies in Arthritis, Rheumatoid by Tanta University are open now, in 1 country. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18–70
Tanta University · Sites in Egypt
Ages 18+
Tanta University · Sites in Egypt
Ages 18–70
Tanta University · Sites in Egypt
Ages 18–70
Tanta University · Sites in Egypt
Ages 18–60
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 4 · Phase 4 4
First in 2019; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 63 across the 14 interventional studies, 30 across the 1 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Tanta University is the lead sponsor of 1,012 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
5 of the studies in Arthritis, Rheumatoid by Tanta University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07800351Phase 3Tanta UniversityNicorandil in Atherosclerosis Risk in Patients With Rheumatoid Arthritis | 2027-02 |
| NCT07401732Tanta UniversityDysphagia in Rheumatoid Arthritis | 2026-11 |
| NCT06998628Tanta UniversityPentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis | 2027-05-30 |
| NCT07901309Tanta UniversityEfficacy and Safety of Dapagliflozin as an Adjunct to Conventional Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis | 2027-06-30 |
| NCT07745426Tanta UniversityClinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid Arthritis | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 15 studies in Arthritis, Rheumatoid by Tanta University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Rheumatoid arthritis (RA) is a long-standing autoimmune inflammatory disease marked by continuous synovial inflammation, which contributes to progressive cartilage and bone damage, eventually resulting in joint destruction. Both inherited genetic factors and environmental exposures substantially contribute to the risk of developing the disease. Additionally, several lifestyle and biological factors including diet, cigarette smoking, hormonal influences, alcohol consumption, gut microbiota, infections, and coffee intake have been implicated in the development and progression of RA. Clinically, RA is frequently characterized by morning stiffness, pain involving the shoulder, neck, and pelvic girdle, impaired mobility, and systemic features including fever.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults aged 23-57 years. Patients meeting the 2010 American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) classification criteria for rheumatoid arthritis (RA).
Patients with active RA, regardless of disease duration. Patients receiving stable doses of permitted concomitant medications, including: Methotrexate (MTX), Nonsteroidal anti-inflammatory drugs (NSAIDs), Selective cyclooxygenase-2 (COX-2) inhibitors, Acetaminophen, and Low-dose oral .
Patients stabilized on combination conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for more than four weeks will be eligible for inclusion.
Exclusion Criteria:
Use of intravenous, intra-articular, or intramuscular within four weeks before initiation of the study medication.
Use of intra-articular sodium hyaluronate within four weeks before initiation of the study medication.
Use of biologic disease-modifying antirheumatic drugs (bDMARDs) within four weeks before initiation of the study medication.
Initiation or use of additional csDMARDs within four weeks before initiation of the study medication, except for patients stabilized on combination csDMARD therapy for more than four weeks.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
control group (n =50) that will receive conventional therapy for RA and placebo
Drug: Placebo
(dapagliflozin group, n = 50) will receive dapagliflozin (10) mg once daily
Drug: Dapagliflozin (10mg Tab)
Placebo will have the same look, and taste of comparative treatment
Dapagliflozin has been reported in several studies to possess lots of pharmacological activities, including anti-inflammatory, and apoptotic-modulation.
Change in disease activity score (DAS-28CRP)
A DAS28 score \>5.1 was classified as high disease activity, 3.2 \< DAS28 ≤ 5.1 as moderate activity, and DAS28 ≤ 3.2 as low. activity, and DAS28 \<2.6 as remission
Time frame: 3 months
Start is estimated for Oct 2026; primary completion for Jun 2027, 8 months later.
Of 29 phase 1/2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 26. This study's planned 8 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin